.jpg)
Oops! Something went wrong while submitting the form.
Services
Continuous glucose monitoring (CGM) is a small wearable sensor that measures interstitial glucose continuously across days or weeks. The data shows glucose patterns across meals, sleep, exercise, stress and the broader day — patterns that single fasting bloodwork misses. For people with type 1 diabetes it is standard care. For people with type 2 diabetes it is increasingly so. For some metabolic and hormonal pictures it can change the clinical conversation.
The wider cultural use of CGM — wellness-industry marketing to non-diabetic populations — has run ahead of the clinical evidence in several directions. Pretty graphs of glucose curves are easy to over-interpret. Mild post-meal rises in a non-diabetic body are not necessarily clinically meaningful. The data can produce useful insight, or it can produce anxious self-monitoring without a clear action.
Continuous glucose monitoring in this pathway is used inside a clinical plan, against defined questions. Where the picture is type 2 diabetes management, insulin resistance investigation, PCOS with metabolic involvement, hormonal change with significant metabolic shift, or other indications where the glucose pattern will inform the plan, CGM is one of the tools the medical part of the team uses. Where the question is "would CGM help me optimise my metabolism" without a clear clinical picture, the responsible answer is often no.
This service is for adults with diabetes, metabolic syndrome, insulin resistance, PCOS, hormonal pictures with significant metabolic involvement, or where glucose patterns will inform the broader hormonal plan. It is not used as a wellness tool for healthy bodies.
The decision to use CGM sits with the medical clinician inside the broader plan. The picture is reviewed — what clinical question the data is being asked to answer, what change it would prompt, and whether the question can be answered without it.
Where CGM is appropriate, the sensor is fitted, the app is set up, and the patient is briefed on what to look for and what not to over-interpret. The aim is for the data to be useful rather than anxiety-producing.
The patient wears the sensor for the planned period — usually one to several sensors across a defined window. A simple symptom and food diary alongside helps the data be read against what the body was doing.
The data is analysed by a clinician who knows the indication. The clinical question the CGM was placed to answer is checked against the data. Where the picture is clear, that is named; where the data raises new questions, those are named too.
The findings change the plan. Medication adjustment for diabetic patients. Nutritional structure changes where indicated. Sleep and circadian work where the data shows nocturnal patterns. Where the findings are unremarkable, that is also useful data — it removes a hypothesis rather than adding a problem.
The CGM data and the plan change are held inside the biio. record so the rest of the team can build on the same picture. Where ongoing CGM is appropriate (type 1 diabetes, certain type 2 contexts), that is built into the long-term plan.
When the CGM work is going well, the data changes a decision. A diabetic patient's medication is adjusted with confidence. An insulin-resistant pattern is identified earlier than fasting bloodwork would have shown. A nutritional structure is revised against what the body actually does with the food.
CGM does not, by itself, treat anything. It is a diagnostic and monitoring tool. The clinical work — medication, nutrition, lifestyle, hormonal management — still sits with the team. Where the data sharpens that work, CGM is useful. Where it does not, the responsible choice is not to use it.